- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06730958
Evaluation of Serum Follistatin-Like Protein 1 Levels in Behcet's Disease and Its Association With Disease Activity
Behçet's disease (BD) is a multi-system auto inflammatory disorder with vasculitic features.
The exact etiological of BD is still obscure, although environmental and genetics factors have been found to be involved in disease pathogenesis.FSTL-1 can act as diagnostic and prognostic biomarkers for Some inflammatory autoimmune diseases including BD.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Behçet's disease (BD) is a multi-system auto inflammatory disorder with vasculitic features Clinical manifestation of BD includes recurrent oral and genital ulcerations, uveitis, skin lesions, vascular, neurological, and gastrointestinal manifestations.The exact etiological of BD is still obscure, although environmental and genetics factors have been found to be involved in disease pathogenesis.
Most of BD manifestations have features of systemic perivasculitis. Cell-mediated immunity has a significant role in BD pathogenesis . Activation of Type 1 helper T (Th1) cell will increase levels of circulating T-lymphocytes, with subsequent increase in the levels of proinflammatory cytokines accounting for most of BD symptoms. These proinflammatory cytokines may be used as an indicator of disease severity. Also Increased macrophage activation, neutrophil chemotaxis, and phagocytosis have been described in BD lesion.
Indeed, the need for studying biomarkers that may drive inflammatory pathways involved in BD pathogenesis is crucial.
Follistatin-like proteins (FLP) belong to the family of acidic cysteine-rich secreted glycoproteins (SPARC) that are highly homologous to the activin-binding protein, follistatin (FST)(7). this group of proteins include five types: FSTL1, FSTL2, FSTL3, FSTL4 and FSTL5.
Follistatin-like protein 1 (FSTL-1) is a soluble gly¬coprotein expressed by mesenchymal cells. It has been involved in various signaling pathways and biological processes. FSTL1 has dual effect in inflammatory processes and has been evaluated in some laboratory models and can serve as pro-inflammatory and anti-inflammatory markers.
During the acute inflammation FSL1 may act as an anti-inflammatory factor, while they exert a pro-inflammatory effect in chronic inflammation. This dual effect has been explained by activation of several signaling pathways.
Although, additional exogenous and endogenous factors, may be involved in such regulation. Increased serum levels FSTL1 levels were found in some of autoimmune systemic diseases including rheumatoid arthritis, Sjogren's syndrome and osteoarthritis. Moreover, the In¬creased serum levels of FSTL-1 where found to be positively correlated with disease activity in some autoim¬mune diseases, including, rheumatoid arthritis (RA), juvenile idiopathic arthritis and systemic lupus ery¬thematosus (SLE).
Based on the above mention findings, FSTL-1 can act as diagnostic and prognostic biomarkers for Some inflammatory autoimmune diseases including BD.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Asyut, Egypt, 71111
- Assiut university hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult BD patients who fulfilling the criteria for the diagnosis by International Team for the Revision of the International Criteria for Bechet's Disease
Exclusion Criteria:
- Individuals with other autoimmune diseases (rheumatoid arthritis dermatomyositis, scleroderma, mixed connective tissue disease).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
control group
healthy matched controls
|
Serum FSL1 level Test principle The kit uses a double-antibody sandwich enzyme-linked immunosorbent assay(ELISA) to assay the level ofHuman Follistatin Like Protein 1(FSTL1) in samples.
Add Follistatin Like Protein 1(FSTL1)to monoclonal antibody.Enzyme well which is pre-coated with Human Follistatin Like Protein1(FSTL1)monoclonal antibody, incubation; then, add Follistatin Like Protein 1(FSTL1)antibodies labeled with biotin, and combined with Streptavidin-HRP to form immune complex; then carry out incubation and washing again to remove the uncombined enzyme.
Then add Chromogen Solution A, B, the color of the liquid changes into the blue, And at the effect of acid, the color finally becomes yellow.
The chroma of color and the concentration of the Human Substance Follistatin Like Protein 1(FSTL1) of sample were positively correlated.
|
|
Behçet's disease
patients with who fulfilling the criteria for the diagnosis by International Team for the Revision of the International Criteria for Bechet's Disease
|
Serum FSL1 level Test principle The kit uses a double-antibody sandwich enzyme-linked immunosorbent assay(ELISA) to assay the level ofHuman Follistatin Like Protein 1(FSTL1) in samples.
Add Follistatin Like Protein 1(FSTL1)to monoclonal antibody.Enzyme well which is pre-coated with Human Follistatin Like Protein1(FSTL1)monoclonal antibody, incubation; then, add Follistatin Like Protein 1(FSTL1)antibodies labeled with biotin, and combined with Streptavidin-HRP to form immune complex; then carry out incubation and washing again to remove the uncombined enzyme.
Then add Chromogen Solution A, B, the color of the liquid changes into the blue, And at the effect of acid, the color finally becomes yellow.
The chroma of color and the concentration of the Human Substance Follistatin Like Protein 1(FSTL1) of sample were positively correlated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
serum FSTL1 level (ng/ml)
Time Frame: 3 months
|
measure serum FSTL1 levels in patients with BD
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sara Farrag, Lecturer, Assiut University
Publications and helpful links
General Publications
- Yazici Y, Hatemi G, Bodaghi B, Cheon JH, Suzuki N, Ambrose N, Yazici H. Behcet syndrome. Nat Rev Dis Primers. 2021 Sep 16;7(1):67. doi: 10.1038/s41572-021-00301-1.
- Tortoriello DV, Sidis Y, Holtzman DA, Holmes WE, Schneyer AL. Human follistatin-related protein: a structural homologue of follistatin with nuclear localization. Endocrinology. 2001 Aug;142(8):3426-34. doi: 10.1210/endo.142.8.8319.
- Kaplan H, Calis M, Yazici C, Gunturk I, Cuce I, Senel AS. Are follistatin-like protein 1 and follistatin-like protein 3 associated with inflammatory processes in patients with familial Mediterranean fever? North Clin Istanb. 2023 Jun 6;10(3):306-313. doi: 10.14744/nci.2022.54189. eCollection 2023.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mouth Diseases
- Stomatognathic Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Genetic Diseases, Inborn
- Eye Diseases
- Skin Diseases
- Skin Diseases, Vascular
- Skin Diseases, Genetic
- Uveal Diseases
- Vasculitis
- Panuveitis
- Uveitis, Anterior
- Uveitis
- Hereditary Autoinflammatory Diseases
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Skin and Connective Tissue Diseases
- Behcet Syndrome
Other Study ID Numbers
- SFA12024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Behcet Syndrome
-
Marmara UniversityHealth Institutes of TurkeyNot yet recruitingPost Thrombotic Syndrome | Behcet Disease | Deep Venous Thromboses | Behcet Disease and Vascular InvolvementTurkey
-
Cairo UniversityRecruiting
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruitingAneurysm | Behcet Syndrome, Vascular TypeChina
-
Cairo UniversityRecruitingMetabolic Syndrome | Behcet DiseaseEgypt
-
Meyer Children's Hospital IRCCSRecruitingBehcet Disease and Vascular InvolvementItaly, United Kingdom
-
Novartis PharmaceuticalsCompleted
-
Janssen Korea, Ltd., KoreaCompleted
Clinical Trials on serum Follistatin-like protein 1
-
Goztepe Prof Dr Suleyman Yalcın City HospitalCompleted
-
Bezmialem Vakif UniversityCompletedPsoriatic Arthritis | Axial SpondyloarthritisTurkey
-
Ankara City Hospital BilkentCompletedEndometriosis | Pelvic Pain | Angiopoietin-like Protein-4Turkey (Türkiye)
-
Hansa Biopharma ABRecruitingKidney Transplantation in Highly Sensitized PatientsUnited Kingdom, Spain, France, Finland, Sweden
-
Hansa Biopharma ABTerminatedKidney Transplantation in Highly Sensitized PatientsUnited States
-
Northwestern UniversityGenentech, Inc.RecruitingMultiple SclerosisUnited States
-
Indiana UniversityEli Lilly and CompanyEnrolling by invitationObesityUnited States
-
Assiut UniversityNot yet recruiting
-
Hansa Biopharma ABCompletedKidney Transplantation in Highly Sensitized PatientsFrance, Belgium, Spain, Netherlands, United Kingdom, Italy, Germany, Sweden, Austria, Czechia, Slovenia
-
Sarepta Therapeutics, Inc.Hansa Biopharma ABTerminatedDuchenne Muscular DystrophySpain